Premium
P4‐271: A NOVEL MICROTECHNOLOGY PLATFORM TO IMPROVE QUANTIFICATION OF ALZHEIMER'S DISEASE CSF BIOMARKERS IN CEREBROSPINAL FLUID
Author(s) -
She Joseph,
Bogaard Patrick T.C.,
Demeyer Leentje,
Vanderstichele Hugo
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.07.041
Subject(s) - multiplex , immunoassay , cerebrospinal fluid , biomarker , computer science , analyte , monoclonal antibody , computational biology , nanotechnology , medicine , bioinformatics , chemistry , antibody , chromatography , pathology , immunology , biology , materials science , biochemistry
World-wide consensus is not reached yet on the need to integrate and use results from cerebrospinal fluid (CSF) protein analysis for early diagnosis of Alzheimer’s disease (AD), for patient enrichment, or to follow-up treatment efficiency. Currently available assay formats have limitations linked to (i) high imprecision or bias, (ii) lot-to-lot variability, and (iii) interference by matrix proteins (= lack of accuracy), all hampering their regulatory approval. So, the AD field might take advantage of new technology platforms, detection systems, or assay procedures.